BioInvent, ThromboGenics Jointly Release TB-402 Phase II Results
TB-402 Phase II trial data was presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy by Peter Verhamme of University of Leuven, Belgium, in a
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The study was a follow-up of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients undergoing major orthopedic surgery showed 25% reduction